Clinical trials: Erdheim-Chester Disease
Erdheim-Chester Disease
Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis. Diagnosis of ECD is based on clinical symptoms, imaging and histology with infiltration of tissues by foamy CD68 positive CD1a negative histiocytes.
- Trial name
- LOVE (NCT02089724)
- Where
- 2 sites in United States, France
- Volunteers
- 20 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Erdheim-Chester Disease
Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease
The study we propose is a pilot phase II, interventional, treatment, open-label, single-arm, efficacy/safety clinical trial of a 6-month treatment with tocilizumab (8 mg/kg once monthly) in adult patients with extraskeletal…
- Trial name
- NCT01727206
- Testing
- Tocilizumab
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Ospedale San Raffaele